These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25348203)
1. Biosimilar ESAs: a comparative review. Wilson P; Wood C J Ren Care; 2015 Mar; 41(1):53-61. PubMed ID: 25348203 [TBL] [Abstract][Full Text] [Related]
2. The emerging role of biosimilar epoetins in nephrology in the United States. Fishbane S; Shah HH Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283 [TBL] [Abstract][Full Text] [Related]
3. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology. Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032 [TBL] [Abstract][Full Text] [Related]
4. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375 [TBL] [Abstract][Full Text] [Related]
6. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Hörl WH Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536 [TBL] [Abstract][Full Text] [Related]
7. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease. Shah HH; Fishbane S Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257 [TBL] [Abstract][Full Text] [Related]
8. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. Covic A; Abraham I Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197 [TBL] [Abstract][Full Text] [Related]
9. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Kalantar-Zadeh K Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147 [TBL] [Abstract][Full Text] [Related]
10. Epoetin biosimilars in Europe: five years on. Mikhail A; Farouk M Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745 [TBL] [Abstract][Full Text] [Related]
11. Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use. Michallet M; Losem C Acta Haematol; 2016; 135(1):44-52. PubMed ID: 26426164 [TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484 [TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States. Anand S; Al-Mondhiry J; Fischer K; Glaspy J Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871 [No Abstract] [Full Text] [Related]
14. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174 [TBL] [Abstract][Full Text] [Related]
15. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl. Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K; Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334 [TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409 [TBL] [Abstract][Full Text] [Related]
17. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience? Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617 [TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study. Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R; BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G; Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010 [TBL] [Abstract][Full Text] [Related]
20. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval? Locatelli F; Del Vecchio L Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]